Lee Dong-Soo, Yu Mina, Jang Hong-Seok, Kim Yeon-Sil, Choi Byung-Ock, Kang Young-Nam, Lee Youn-Soo, Kim Dong-Chul, Hong Yong-Kil, Jeun Sin-Soo, Yoon Sei-Chul
Department of Radiation Oncology, The Cancer Center of Seoul St. Mary's Hospital, The Catholic University of Korea, Seoul, Korea.
Radiat Oncol J. 2011 Sep;29(3):147-55. doi: 10.3857/roj.2011.29.3.147. Epub 2011 Sep 30.
This study was designed to determine the influencing factors and clinical course of pathologically proven cases of radiation-induced brain injury (RIBI).
The pathologic records of twelve patients were reviewed; these patients underwent surgery following radiotherapy due to disease progression found by follow-up imaging. However, they were finally diagnosed with RIBI. All patients had been treated with 3-dimensional conventional fractionated radiotherapy and/or radiosurgery for primary or metastatic brain tumors with or without chemotherapy. The histological distribution was as follows: two falx meningioma, six glioblastoma multiform (GBM), two anaplastic oligodendroglioma, one low grade oligodendroglioma, and one small cell lung cancer with brain metastasis.
Radiation necrosis was noted in eight patients and the remaining four were diagnosed with radiation change. Gender (p = 0.061) and biologically equivalent dose (BED)(3) (p = 0.084) were the only marginally influencing factors of radiation necrosis. Median time to RIBI was 7.3 months (range, 0.5 to 61 months). Three prolonged survivors with GBM were observed. In the subgroup analysis of high grade gliomas, RIBI that developed <6 months after radiotherapy was associated with inferior overall survival rates compared to cases of RIBI that occurred ≥6 months (p = 0.085).
Our study demonstrated that RIBI could occur in early periods after conventional fractionated brain radiotherapy within normal tolerable dose ranges. Studies with a larger number of patients are required to identify the strong influencing factors for RIBI development.
本研究旨在确定经病理证实的放射性脑损伤(RIBI)病例的影响因素及临床病程。
回顾了12例患者的病理记录;这些患者因随访影像发现疾病进展在放疗后接受了手术。然而,他们最终被诊断为RIBI。所有患者均接受了三维常规分割放疗和/或立体定向放射外科治疗原发性或转移性脑肿瘤,有或没有化疗。组织学分布如下:2例镰旁脑膜瘤、6例多形性胶质母细胞瘤(GBM)、2例间变性少突胶质细胞瘤、1例低级别少突胶质细胞瘤和1例脑转移小细胞肺癌。
8例患者出现放射性坏死,其余4例被诊断为放射性改变。性别(p = 0.061)和生物等效剂量(BED)(3)(p = 0.084)是放射性坏死的仅有的边缘影响因素。RIBI的中位时间为7.3个月(范围0.5至61个月)。观察到3例GBM长期存活者。在高级别胶质瘤的亚组分析中,放疗后<6个月发生的RIBI与≥6个月发生的RIBI相比,总生存率较差(p = 0.085)。
我们的研究表明,在常规分割脑放疗后的早期,在正常可耐受剂量范围内可能发生RIBI。需要对更多患者进行研究以确定RIBI发生的强烈影响因素。